Drug
Xmt 1536
Xmt 1536: highest development phase Phase 1, developed by Mersana Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Mersana Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| XMT-1536 (Upifitamab Rilsodotin) NCT04907968 | Phase 1 | Platinum-sensitive Ovarian Cancer (UPGRADE-A) |
Latest
No recent events.
Follow Xmt 1536 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.